In a Netflix documentary, Bryan Johnson, a tech entrepreneur, discussed his morning routine involving various therapies, exercise, and supplements from his longevity start-up, Blueprint, aimed at achieving the lowest biological age. However, Johnson’s use of legal confidentiality agreements to control his image and silence employees has led to complaints and concerns about the company’s financial challenges and product quality issues. Former employees have raised questions about the effectiveness and safety of Blueprint’s health supplements, with some experiencing side effects, while Johnson has faced criticism for cherry-picking positive metrics from his health experiments. Additionally, Johnson’s past use of confidentiality agreements, including with his former fiancée, has sparked legal battles and public scrutiny, leading current and former employees to challenge these agreements through complaints filed with the National Labor Relations Board.
Full Article
Why NovoCure Stock Was Withering on Wednesday
Cancer-focused biotech NovoCure (NVCR -4.07%) saw its stock price target cut by Wedbush analyst David Nierengarten from $29 to $27, leading to a nearly 5% drop in stock value amidst bearish sentiment. Despite a 21% year-over-year revenue growth in Q4 2024, the company reported a net loss of $0.61 per share, worse than analysts expected. While investors are impatient for positive news, the company remains well-positioned in cancer treatment, suggesting it may be a discount...
Read more